Literature DB >> 27613159

From Good to Better: New Dutch Guidelines for Economic Evaluations in Healthcare.

Matthijs Versteegh1, Saskia Knies2,3, Werner Brouwer4,5.   

Abstract

Mesh：

Year:  2016        PMID： 27613159     DOI： 10.1007/s40273-016-0431-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  22 in total

1.  Should the consumption of survivors be included as a cost in cost-utility analysis?

Authors:  John A Nyman
Journal:  Health Econ       Date:  2004-05       Impact factor: 3.046

2.  Accounting for future costs in medical cost-effectiveness analysis.

Authors:  D Meltzer
Journal:  J Health Econ       Date:  1997-02       Impact factor: 3.883

3.  The friction cost method for measuring indirect costs of disease.

Authors:  M A Koopmanschap; F F Rutten; B M van Ineveld; L van Roijen
Journal:  J Health Econ       Date:  1995-06       Impact factor: 3.883

4.  Discounting and decision making in the economic evaluation of health-care technologies.

Authors:  Karl Claxton; Mike Paulden; Hugh Gravelle; Werner Brouwer; Anthony J Culyer
Journal:  Health Econ       Date:  2010-05-12       Impact factor: 3.046

Review 5.  Unpaid work in health economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Soc Sci Med       Date:  2015-09-09       Impact factor: 4.634

6.  Towards a new approach for estimating indirect costs of disease.

Authors:  M A Koopmanschap; B M van Ineveld
Journal:  Soc Sci Med       Date:  1992-05       Impact factor: 4.634

7.  How to include informal care in economic evaluations.

Authors:  Renske J Hoefman; Job van Exel; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

Review 8.  Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions?

Authors:  David R Rappange; Pieter H M van Baal; N Job A van Exel; Talitha L Feenstra; Frans F H Rutten; Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  How to estimate productivity costs in economic evaluations.

Authors:  Marieke Krol; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

Review 10.  Patient and general public preferences for health states: A call to reconsider current guidelines.

Authors:  M M Versteegh; W B F Brouwer
Journal:  Soc Sci Med       Date:  2016-07-31       Impact factor: 4.634
View more
  31 in total

1.  Beneluxa: What are the Prospects for Collective Bargaining on Pharmaceutical Prices Given Diverse Health Technology Assessment Processes?

Authors:  James F O'Mahony
Journal:  Pharmacoeconomics       Date:  2019-05       Impact factor: 4.981

2.  Spillover Effects on Caregivers' and Family Members' Utility: A Systematic Review of the Literature.

Authors:  Eve Wittenberg; Lyndon P James; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

3.  Dutch guidelines for economic evaluation: 'from good to better' in theory but further away from pharmaceuticals in practice?

Authors:  Livio Garattini; Anna Padula
Journal:  J R Soc Med       Date:  2017-01-24       Impact factor: 5.344

Review 4.  International Regulations and Recommendations for Utility Data for Health Technology Assessment.

Authors:  Donna Rowen; Ismail Azzabi Zouraq; Helene Chevrou-Severac; Ben van Hout
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

5.  Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Authors:  Amir Ansaripour; Carin A Uyl-de Groot; W Ken Redekop
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981

Review 6.  Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic stem cell transplantation in patients with hematological malignancy.

Authors:  Shigeo Fuji; Arnon Nagler; Mohamad Mohty; Bipin Savani; Roni Shouval
Journal:  Bone Marrow Transplant       Date:  2020-01-13       Impact factor: 5.483

7.  A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.

Authors:  Elahe Khorasani; Majid Davari; Abbas Kebriaeezadeh; Farshad Fatemi; Ali Akbari Sari; Vida Varahrami
Journal:  Eur J Health Econ       Date:  2022-03-02

8.  Assessing the validity of the ICECAP-A capability measure for adults with depression.

Authors:  Paul Mark Mitchell; Hareth Al-Janabi; Sarah Byford; Willem Kuyken; Jeff Richardson; Angelo Iezzi; Joanna Coast
Journal:  BMC Psychiatry       Date:  2017-02-02       Impact factor: 3.630

9.  Update of the Dutch manual for costing studies in health care.

Authors:  Tim A Kanters; Clazien A M Bouwmans; Naomi van der Linden; Siok Swan Tan; Leona Hakkaart-van Roijen
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

10.  Cost-effectiveness of single-layer versus double-layer uterine closure during caesarean section on postmenstrual spotting: economic evaluation alongside a randomised controlled trial.

Authors:  Sanne I Stegwee; Ângela J Ben; Mohamed El Alili; Lucet F van der Voet; Christianne J M de Groot; Judith E Bosmans; Judith A F Huirne
Journal:  BMJ Open       Date:  2021-07-02       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.